Jupiter Topco LLC Makes New Investment in Progyny, Inc. $PGNY

Jupiter Topco LLC bought a new position in Progyny, Inc. (NASDAQ:PGNY) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 450,412 shares of the company’s stock, valued at approximately $12,986,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Progyny during the fourth quarter valued at approximately $25,000. Hantz Financial Services Inc. raised its holdings in Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after purchasing an additional 742 shares in the last quarter. Allworth Financial LP purchased a new position in Progyny during the second quarter valued at $94,000. Canada Pension Plan Investment Board purchased a new position in Progyny during the second quarter valued at $77,000. Finally, Quarry LP boosted its holdings in shares of Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after buying an additional 3,427 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on PGNY shares. Truist Financial upped their target price on shares of Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Leerink Partners set a $38.00 price target on shares of Progyny in a research report on Wednesday, July 22nd. Wall Street Zen lowered shares of Progyny from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. KeyCorp upped their price objective on shares of Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Finally, JPMorgan Chase & Co. raised their target price on shares of Progyny from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.91.

Progyny Trading Up 0.5%

NASDAQ PGNY opened at $26.00 on Friday. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $33.06. The stock’s fifty day moving average price is $29.08 and its 200-day moving average price is $23.63. The stock has a market cap of $1.99 billion, a P/E ratio of 28.26, a P/E/G ratio of 1.79 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The company had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. Progyny’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, analysts forecast that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.

Progyny declared that its board has authorized a stock buyback program on Tuesday, May 26th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to buy up to 10.3% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity

In related news, CFO Mark S. Livingston sold 2,517 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $25.50, for a total value of $64,183.50. Following the completion of the transaction, the chief financial officer directly owned 74,688 shares in the company, valued at $1,904,544. The trade was a 3.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total value of $39,137.40. Following the completion of the transaction, the insider directly owned 59,117 shares in the company, valued at $1,512,212.86. This trade represents a 2.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 13,563 shares of company stock worth $351,968. Corporate insiders own 9.90% of the company’s stock.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.